Muscarinic Acetylcholine Receptor M4 (CHRM4)-Pipeline Review, H1 2017

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Pipeline Review, H1 2017


  • Products Id :- GMDHC0895TDB
  • |
  • Pages: 61
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Pipeline Review, H1 2017

Summary

Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The latest report Muscarinic Acetylcholine Receptor M4 (CHRM4)-Pipeline Review, H1 2017, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 1 and 6 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Mouth and Dental Disorders and Ophthalmology which include indications Alzheimer Disease, Schizophrenia, Psychosis, Amnesia, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Epilepsy, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Parkinson Disease, Presbyopia, Rett Syndrome and Sialorrhoea.

Furthermore, this report also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)

The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects

The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Overview

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Companies Involved in Therapeutics Development

Anavex Life Sciences Corp

AstraZeneca Plc

Heptares Therapeutics Ltd

Karuna Pharmaceuticals Inc

NeuroHealing Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Drug Profiles

(aceclidine + tropicamide)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ANAVEX-273 + donepezil hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(trospium chloride + xanomeline tartrate)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANAVEX-273-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize M1 and M4 Muscarinic Acetylcholine Receptors for Psychosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tropicamide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0467154-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-6000918-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Dormant Products

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Discontinued Products

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Product Development Milestones

Featured News & Press Releases

May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference

May 19, 2017: Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings

Jan 19, 2017: Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017

Dec 15, 2016: Karuna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimers

Dec 08, 2016: Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer disease Patients

Nov 22, 2016: Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimers Disease

Sep 28, 2016: Anavex Compound to be Tested in Biogen Neurological Protection Model

Sep 22, 2016: Anavex Life Sciences Drug Shows Efficacy to Support Potential Disease Modification in Parkinson Disease

Sep 12, 2016: Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate

Jul 29, 2016: Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer Patients Presented at AAIC 2016

Jul 27, 2016: Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer Patients at AAIC 2016

Jul 24, 2016: Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer Patients at AAIC 2016

Jul 12, 2016: Anavex to Present at the Alzheimer Association International Conference (AAIC) 2016

Jun 22, 2016: Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms

Jun 06, 2016: Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X-Autism-Related Disorders

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Anavex Life Sciences Corp, H1 2017

Pipeline by AstraZeneca Plc, H1 2017

Pipeline by Heptares Therapeutics Ltd, H1 2017

Pipeline by Karuna Pharmaceuticals Inc, H1 2017

Pipeline by NeuroHealing Pharmaceuticals Inc, H1 2017

Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Anavex Life Sciences Corp

AstraZeneca Plc

Heptares Therapeutics Ltd

Karuna Pharmaceuticals Inc

NeuroHealing Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Muscarinic Acetylcholine Receptor M4 (CHRM4) Therapeutic Products under Development, Key Players in Muscarinic Acetylcholine Receptor M4 (CHRM4) Therapeutics, Muscarinic Acetylcholine Receptor M4 (CHRM4) Pipeline Overview, Muscarinic Acetylcholine Receptor M4 (CHRM4) Pipeline, Muscarinic Acetylcholine Receptor M4 (CHRM4) Pipeline Assessment

select a license
Single User License
USD 3500 INR 245000
Site License
USD 7000 INR 490000
Corporate User License
USD 10500 INR 735000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com